EUVIMEDEUVIMED entdecken
Open Access

Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease

Dolan Sondhi iD, Stephen M Kaminsky iD, Jonathan B Rosenberg, Mahboubeh R Rostami, Neil R Hackett, Ronald G Crystal iD

Human Gene Therapy · 2025

DOI: 10.1089/hum.2024.182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Dolan Sondhi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Genetic Therapy, Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CLN2 disease (late infantile neuronal ceroid lipofuscinosis) is an autosomal recessive, neurodegenerative lysosomal storage disease that results from loss of function mutations in the CLN2 gene, which encodes tripeptidyl peptidase 1. It affects the central nervous system (CNS) with progressive neurodegeneration and early death, typically at ages from 8 to 12 years. Twenty years ago, our phase I clinical trial treated subjects with CLN2 disease by a catheter-based CNS administration of an adeno-associated virus vector serotype 2 (AAV2) expressing the CLN2 gene. Here we present an analysis of the survival of the 10 treated children and find 2 distinct survival groups with a wide disparity in survival. Group 1 ( n = 7) had the typical mean survival of 8.8 ± 0.5 years of age, 3.8 ± 0.6 years post-therapy. Group 2 ( n = 3) had a markedly longer mean survival of 23.4 ± 2.4 years of age and 14.9 ± 2.8 years post-therapy ( p < 0.00002, survival of group 1 vs. group 2). Long survivors (group 2) at the time of treatment were older (group 1: 5.0 ± 0.6 years; group 2: 8.5 ± 0.9 years; p < 0.02); had similar disease severity (Hamburg clinical score group 1: 4.7 ± 0.5, group 2: 3 ± 0.0, p > 0.05); and had larger CNS ventricular volume (81.1 ± 22.2 cm 3 vs. 27.3 ± 7.2 cm 3 for group 1; p < 0.02). While the genotype of 3, group 2 subjects, had one allele (509-1G>C) identical to that of three in group 1, the second allele was different. This was unlikely to explain the survival difference, as alleles for both groups were equally predicted deleterious by the Combined Annotation-Dependent Depletion score: 34.9 ± 0.7 and 32.8 ± 0.3 for groups 1 and 2, respectively (a score of >20 is considered deleterious). This represents one of the longest survival studies (up to 20 years) of AAV-treated individuals with hereditary disorders and demonstrates variability of therapeutic efficacy where the genotype on its own has no apparent survival advantage. Protocol registration numbers for the original study: NCT00151216 and NCT00151268; www.clinicaltrials.gov .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuronal Ceroid-LipofuscinosesGenetic TherapyDependovirusGenetic VectorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesAminopeptidasesCentral Nervous SystemHumansTripeptidyl-Peptidase 1ChildFemaleMaleChild, PreschoolAdolescentSurvival AnalysisTreatment Outcome

Stichwörter der Autor:innen

AAV2CADD analysisCLN2 diseaseadeno-associated virusgenotypesurvival

Substanzen

Tripeptidyl-Peptidase 1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesTPP1 protein, humanAminopeptidases

Autor:innen und Institutionen

  • Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA.

ORCID-Profile: Dolan Sondhi, Stephen M Kaminsky, Ronald G Crystal

Förderung

  • NINDS NIH HHS
  • NCRR NIH HHS

Zitieren

APA

Sondhi, D., Kaminsky, S. M., Rosenberg, J. B., Rostami, M. R., Hackett, N. R., & Crystal, R. G. (2025). Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease. Human Gene Therapy. https://doi.org/10.1089/hum.2024.182

Vancouver

Sondhi D, Kaminsky SM, Rosenberg JB, Rostami MR, Hackett NR, Crystal RG. Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease. Human Gene Therapy. 2025. doi:10.1089/hum.2024.182

BibTeX
@article{Sondhi2025,
  author = {Sondhi, Dolan and Kaminsky, Stephen M and Rosenberg, Jonathan B and Rostami, Mahboubeh R and Hackett, Neil R and Crystal, Ronald G},
  title = {Twenty-Year Survival Analysis of Adeno-Associated Virus Vector Serotype 2-Mediated Gene Therapy to the Central Nervous System for CLN2 Disease},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1089/hum.2024.182}
}
Kostenlos starten →